共 112 条
[1]
Siu AL(2016)Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 164 279-296
[2]
Melnikow J(2016)Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 164 268-278
[3]
Fenton JJ(2014)Twenty-five-year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial BMJ 348 g366-5312
[4]
Whitlock EP(2007)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287-965
[5]
Miglioretti DL(2013)Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 31 961-e79
[6]
Weyrich MS(2008)National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers Clin Chem 54 e11-155
[7]
Thompson JH(2014)Tumor marker usage and medical care costs among older early stage breast cancer survivors J Clin Oncol 33 149-60
[8]
Miller AB(2007)Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients Indian J Clin Biochem 22 57-1157
[9]
Wall C(2015)Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer PLoS One 10 e0133830-1688
[10]
Baines CJ(2010)Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer Clin Chem 56 1148-56